Vaxcyte is a clinical-stage biotechnology company developing novel protein-based vaccines, including advanced pneumococcal conjugate vaccine candidates.
| Filer | 13FScore | This quarter | Shares | Value | % of their book |
|---|---|---|---|---|---|
| Paul Tudor Jones / Tudor | 61 | Trimmed -63% | 11,800 | $671,420 | 0.0% |
| Bridgewater | 55 | Trimmed -20% | 40,377 | $2,297,451 | 0.0% |
| Report | Date | Stance |
|---|---|---|
| #97 — Rough Seas Make Strong Sailors: Navigating the Healthcare Policy Tsunami | 2025-05-28 | WATCH |
| #84 — Market Memo: Healthcare's AI-Powered Trump Card | 2025-02-09 | SHORT |
Every tracked holder of this name, sorted new → added → flat → trimmed. Shares = reported 13F share count; Value as reported (a few managers file values in $thousands). Generated 2026-11-17.